ArticleJournal of applied clinical medical physics2026
Generalizability of deep learning-based dose conversion model in proton beam therapy.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn proton beam therapy (PBT), the analytical pencil beam (PB) algorithm involves dose uncertainties in inhomogeneous regions, making accurate Monte Carlo (MC) dose calculation desirable but time-consuming. Deep learning, converting the dose calculated by the PB algorithm into an MC-equivalent dose distribution, can resolve the trade-off between calculation accuracy and speed. Training a DL-based dose conversion model that can be applied to any tumor site would be ideal; however, the appropriate training regions and its generalizability remain unclear. PURPOSE: We developed a DL-based dose conversion model trained on four representative tumor sites (i.e., head and neck, lung, liver, and prostate), and evaluated its generalizability.
methodsData from 339 patients (a total of 1147 beams) were used. PB doses were obtained from the treatment planning system, and MC doses were calculated using an in-house MC platform. Our developed DL-based dose conversion model was designed to input a treatment planning computed tomography image and PB dose in a single field and output an MC-equivalent dose. The model's generalizability was evaluated on untrained tumor sites, including the esophagus, pancreas, colorectum, brain, breast, cervix, and limb bone and soft tissue. The conversion performance was assessed using 3D γ-analysis and the Dice similarity coefficient (DSC) for isodose volumes.
resultsFor most untrained tumor sites, the model achieved average γ-passing rates of ≥90% with a criterion of 3%/2 mm. The esophagus, breast, which are close to the lung, and limb bone and soft tissue showed slightly lower passing rates of 91.3%, 85.9%, and 89.1%, respectively. The average DSC values exceeded 0.8 for most untrained tumor sites.
conclusionThe proposed DL-based dose conversion model demonstrated high accuracy and generalizability, even for untrained tumor sites. These findings suggest that the model can be adapted to biases in collecting disease data at each PBT center and for rare diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.